Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 4,080
Out of 5,090 analysts
81
Total ratings
30.67%
Success rate
-19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $10.61 | +22.53% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $19.50 | +284.62% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $31.74 | -14.93% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $38.78 | +90.82% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $21.15 | -47.99% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $12.11 | +321.14% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $5.75 | +1,204.35% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.07 | +607.21% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $79.64 | -62.33% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.37 | +775.91% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $27.78 | +1,160.13% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.18 | +155.40% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $11.95 | +134.31% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $17.30 | +206.36% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $10.61
Upside: +22.53%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $19.50
Upside: +284.62%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $31.74
Upside: -14.93%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $38.78
Upside: +90.82%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $21.15
Upside: -47.99%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $12.11
Upside: +321.14%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $5.75
Upside: +1,204.35%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.07
Upside: +607.21%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $79.64
Upside: -62.33%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.37
Upside: +775.91%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $27.78
Upside: +1,160.13%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.18
Upside: +155.40%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $11.95
Upside: +134.31%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $17.30
Upside: +206.36%